Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

This study has been completed.
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd. Identifier:
First received: September 13, 2005
Last updated: September 25, 2006
Last verified: September 2006

In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.

Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: miglitol
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:


Ages Eligible for Study:   20 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • type2 diabetes
  • postprandial plasma glucose levels ≧180mg/dl

Exclusion Criteria:

  • type1 diabetes
  • AST(GOT) or ALT(GPT) ≧100IU/l
  • creatinine ≧2.0mg/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00213122

Ibaraki, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Study Director: Clinical Promotiom Group Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information

No publications provided Identifier: NCT00213122     History of Changes
Other Study ID Numbers: MG1007
Study First Received: September 13, 2005
Last Updated: September 25, 2006
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 19, 2014